The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentLaura N Eadie, Deborah L. White, Michael Osborn et al.|Leukemia|2016Cited by 68
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Timothy P. Hughes|Oncotarget|2018Cited by 59
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk diseaseMichelle O. Forgione, Deborah L. White, Barbara J. McClure et al.|Cancer Letters|2019Cited by 49